Evogene (EVGN) Stock Skyrockets 100% on AI Hype and Google News Surge
Another day, another stock riding the AI hype train to absurd valuations—this time it''s Evogene (EVGN) doubling overnight. Google News algorithms apparently caught wind of some undisclosed ''breakthrough,'' and traders piled in like it was 2021 again.
No actual revenue or product updates? No problem. The market''s happy to bet on vaporware as long as it''s wrapped in an AI buzzword bow. Meanwhile, serious biotech firms grinding out real research roll their eyes.
Will the rally hold? Unlikely—but enjoy the volatility while it lasts. Just remember: what AI giveth, AI taketh away (usually faster).
Confident Investing Starts Here:
- Easily unpack a company''s performance with TipRanks'' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks'' Smart Value Newsletter
What Is the AI Foundation Model
The AI model was trained on a large dataset of 38 billion molecular structures. It delivers around 90% precision in generating novel, high-quality molecules, compared to about 29% for traditional GPT-based AI models. According to the company, the model can evaluate multiple product criteria simultaneously, rather than doing so in a step-by-step process, including potency, safety, and patentability. This enables faster screening and more effective targeting of candidates who are both effective and IP-ready.
The tool is expected to help in the development of new drug candidates and crop protection solutions. In pharmaceuticals, it could reduce costly failures in later-stage development. In agriculture, it may support the creation of more sustainable and effective agrochemicals. Both sectors face rising R&D costs and stricter regulatory demands, and AI tools like this aim to accelerate and streamline the discovery process.
The model runs on Google Cloud’s Vertex AI platform and makes use of high-performance GPUs and scalable compute. This partnership allows Evogene to handle the significant computational demands of generative AI without building its own infrastructure. Development is already underway on version 2.0 of the model. While the company is still in the early stages of monetization, developments like this could open the door for licensing deals or strategic partnerships.
EVGN’s Next Goal
EVGN is up a modest 2.67% year-to-date, but the real upgrade could stem from successfully converting its technical progress into commercial success. For now, this AI foundation model adds a new LAYER to the company’s platform and may enhance its positioning in the small-molecule discovery market. So, potential investors may want to watch this one.
Is Evogene a Good Stock to Buy?
Based on two analysts, Evogene boasts a Moderate Buy rating, with an average EVGN stock price target of $3.50. This implies an 82.29% upside.
